Fitzpatrick Wins Summary Judgment Motion in Lamictal® Case
On July 15, 2004, Chief Judge John W. Bissell of the District of New Jersey granted summary judgment in favor of Fitzpatrick client GlaxoSmithKline that it did not commit inequitable conduct before the Patent and Trademark Office in obtaining its patent on the epilepsy drug Lamictal®. The Court found that Teva had failed to meet its burden of demonstrating either the materiality of the non-disclosed information or any intent to deceive on the part of the applicants. Fitzpatrick's litigation team was led by partners Nicholas M. Cannella and Brian V. Slater.
View Attachment (PDF)
Back to Representative Cases
- Related Practice Area
- Related Industries